Figure 6.

ADAM8 Marks TKI-Resistant Residual CML Cells in BM of CML-CP Patients with Optimal TKI Response under Treatment with TKI

(A) A scheme of limiting dilution assay.

(B) Characteristics of CML-CP patients with optimal TKI response under treatment with TKIs.

(C) Limiting dilution assay for CML-CP patients with optimal TKI response under treatment with TKIs. Residual CML cells are concentrated more in the ADAM8+ subpopulation than in the ADAM8− subpopulation. Data for each patient show n = 1. CI, confidence interval.

(D) Frequency of residual CML cells in CML-CP patients with optimal TKI response. Data for each patient show n = 1.

Error bars represent 95% CI. p values: chi-square test. ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001.